Last $878.00 MXN
Change Today +4.00 / 0.46%
Volume 51.2K
MRK* On Other Exchanges
Symbol
Exchange
New York
Mexico
Frankfurt
As of 4:09 PM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

merck & co. inc. (MRK*) Snapshot

Open
$880.88
Previous Close
$874.00
Day High
$880.88
Day Low
$878.00
52 Week High
01/23/15 - $920.10
52 Week Low
05/21/14 - $703.04
Market Cap
2.5T
Average Volume 10 Days
5.5K
EPS TTM
--
Shares Outstanding
2.8B
EX-Date
03/12/15
P/E TM
--
Dividend
$1.80
Dividend Yield
2.73%
Current Stock Chart for MERCK & CO. INC. (MRK*)

merck & co. inc. (MRK*) Details

Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents for use in surgery; anti-bacterial products for skin and skin structure infections; antidepressants; ophthalmic and cholesterol modification products; non-sedating antihistamine; and vaginal contraceptive implants. In addition, the company provides products to prevent chemotherapy-induced and post-operative nausea and vomiting; to treat brain tumors and melanoma; to prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers animal health products, including antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics for, and vaccines against bacterial and viral disease in fish. Additionally, the company provides companion animal products, such as diabetes mellitus treatment drugs and vaccines for dogs and cats; ointments for acute and chronic otitis; anthelmintic products; chewable tablets to kill fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. The company serves drug wholesalers and retailers, hospitals, government entities and agencies, physicians, physician distributors, veterinarians, distributors, and animal producers, as well as managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

70,000 Employees
Last Reported Date: 02/27/15
Founded in 1891

merck & co. inc. (MRK*) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Executive Vice President and President of Mer...
Total Annual Compensation: $1.2M
President of Global Human Health and Executiv...
Total Annual Compensation: $957.3K
Compensation as of Fiscal Year 2013.

merck & co. inc. (MRK*) Key Developments

Merck Declares Unchanged Quarterly Dividend

Merck Declares Unchanged Quarterly Dividend Merck & Company (MRK) has declared a quarterly dividend of $0.45 per share, unchanged from the previous quarter. The dividend is payable on April 8 to shareholders of record as of March 16.

The Medicines Patent Pool Signs Licensing Agreement with MSD for Paediatric Formulations of Raltegravir

The Medicines Patent Pool (MPP) announced a licence with MSD, known as Merck in the United States and Canada, for paediatric formulations of raltegravir, a key medicine approved for children living with HIV four weeks of age and older. With the new licence, generic manufacturers and other companies based anywhere in the world can develop, manufacture and sell low cost, paediatric versions of raltegravir in countries with the highest burden of disease, where 98% of children with HIV in the developing world live. The World Health Organization recommends raltegravir as a component of paediatric third-line treatment. Its recent extended approval for infants as young as a month suggests its potential in filling an important gap in paediatric care. The medicine's current availability as chewable tablets and granules for oral suspension could potentially ease implementation in paediatric programmes. The medicine is currently in clinical studies for potential use in newborns.

Merck Collaborates with University of Indonesia and Maharashtra University to Build Diabetes and Thyroid Dysfunction Healthcare Capacity in Asia

Merck introduced European Accredited Clinical Diabetes management for more than 5,000 medical and pharmacy students of both universities as part of Merck Capacity Advancement Program (CAP) in Asia. The 5 years program has been developed by EXCEMED - Excellence in Medical Education and is accredited by the European Accreditation Council of Continuous Medical Education (EACCME). The course will be taught by European and local Diabetes and Thyroid experts. Based on its long experience in diabetes management, which began in 1957 with the development of metformin, Merck seeks to raise awareness of diabetes by supporting the healthcare system to prevent, diagnose and manage the condition effectively. As part of the Merck Capacity Advancement Program, by end of 2015, more than 5,000 medical students in partnership with African universities such as University of Nairobi, Makerere University, Namibia University and University of Ghana, in addition to Asian universities such as Maharashtra university, India and University of Indonesia will benefit from European-accredited clinical diabetes and chronic diseases management training, which is seeking to equip them with skills to avert the diabetes epidemic. Merck is planning to target more than 15,000 students by the end of 2018 expanding to more Universities in the developing countries.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MRK*:MM $878.00 MXN +4.00

MRK* Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $103.83 USD +0.30
GlaxoSmithKline PLC 1,554 GBp +12.50
Pfizer Inc $34.77 USD +0.45
Roche Holding AG SFr.261.00 CHF +2.20
Sanofi €86.40 EUR -1.30
View Industry Companies
 

Industry Analysis

MRK*

Industry Average

Valuation MRK* Industry Range
Price/Earnings 14.4x
Price/Sales 4.0x
Price/Book 3.4x
Price/Cash Flow 14.0x
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERCK & CO. INC., please visit www.merck.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.